E

Endologix

Medical devices for durable vascular repair

Senior Regulatory Affairs Specialist

Full-TimeDeadline 10/1/27
$110k - $127.5k/yr
Senior
Bachelor's, Master's
California, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a scientific discipline or equivalent education and experience is required.
  • A minimum of 5 years of medical device experience and at least 1 year of Regulatory Affairs experience is required with a bachelor's degree.
  • Experience leading successful Class III regulatory submissions.
  • In-depth knowledge of FDA, EU MDR, and global medical device regulations, including experience preparing and maintaining regulatory submissions and technical documentation.
  • Strong understanding of design controls, ISO 13485, and risk management principles (ISO 14971).
  • Advanced technical proficiency to read, analyze, and interpret complex technical documents and publications.
  • Ability to interpret complex data and produce clear, accurate, and compliant documentation.
  • Ability to manage multiple regulatory submissions, track competing deadlines, and collaborate with cross-functional teams.
  • Ability to partner with R&D, Clinical, Quality, Marketing, and Manufacturing teams.
  • Ability to ensure labeling, advertising, and promotional materials meet regulatory requirements.
  • Understanding of how regulatory decisions influence product lifecycle management, market strategy, and commercialization.
  • Ability to monitor evolving global regulations and guidance.
  • Proficiency in Microsoft Word, Excel, PowerPoint, and Adobe Acrobat.
Responsibilities
  • Develop, implement, and maintain regulatory processes and standard operating procedures to ensure compliance with current and evolving global regulations and prioritize product quality and patient safety.
  • Provide regulatory leadership and input to product lifecycle planning.
  • Assist in developing and executing multi-country regulatory strategies for the United States, European Union, and Canada.
  • Propose regulatory strategies to resolve complex regulatory challenges while maintaining compliance.
  • Determine, interpret, and support fulfillment of submission and approval requirements.
  • Review analytical and clinical protocols to ensure appropriate data collection for regulatory submissions.
  • Participate in cross-functional risk management activities to mitigate patient, product, and compliance risks.
  • Stay current on new and revised regulations, guidance, and industry trends; evaluate their impact and drive regulatory decisions.
  • Anticipate regulatory obstacles and emerging issues throughout the product lifecycle and collaborate across teams on compliant solutions.
  • Serve as a core regulatory team member and provide regulatory leadership and partnership to cross-functional project teams.
  • Assess quality, preclinical, and clinical documentation for acceptability and regulatory submission readiness.
  • Compile, prepare, review, and submit regulatory submissions to global regulatory authorities; interact with authorities to support timely approvals.
  • Build relationships with internal and external stakeholders, communicate with diverse audiences, and advise on complex regulatory matters.
  • Monitor regulatory changes affecting submission strategies and communicate implications to stakeholders.
  • Track applications under regulatory review and communicate status, risks, and timelines to cross-functional partners.
  • Monitor and submit required regulatory reports and provide accurate, timely responses.
  • Evaluate proposed preclinical, clinical, design, and manufacturing changes to determine regulatory filing strategies.
  • Negotiate and interact with regulatory authorities during development and review processes to facilitate submission approvals.
  • Provide strategic regulatory input and technical guidance to development teams.
  • Review proposed post-market changes to determine regulatory impact and required submission pathways.
  • Maintain and update Technical Files and Design Dossiers.
  • Oversee regulatory processes related to annual licenses, registrations, listings, and patent information.
  • Ensure ongoing compliance with post-market regulatory requirements.
  • Perform other duties as assigned in support of team objectives and organizational priorities.
Desired Qualifications
  • A master's degree with at least 1 year of related experience is preferred.
  • With a master's degree, 3 years of medical device experience and at least 1 year of Regulatory Affairs experience are preferred.

About the company

Endologix develops vascular medical devices to treat abdominal aortic aneurysms (AAA) and peripheral artery disease (PAD). It sells advanced graft systems used inside blood vessels to repair weakened arteries and improve blood flow. Its products, such as AFX, Ovation, and ALTO, are designed to fit and work with a patient's own artery anatomy to provide durable, stable repairs and preserve the natural bifurcation of the vessels. The company differentiates itself through a focus on preserving native vascular anatomy, offering personalized repair options, and pursuing ongoing clinical excellence and product refinement. Its goal is to help healthcare professionals deliver better outcomes for patients with vascular conditions by providing reliable, long-lasting devices that address unmet needs in vascular care.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Santa Rosa, California

Founded

1992

Get referred to Endologix

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Endologix closed Pounce on May 18, 2026, adding FDA-cleared peripheral thrombectomy.
  • DETOUR2 2026 publication strengthened commercial credibility for complex femoropopliteal disease treatment.
  • Steve Deitsch joined the board in May 2026, signaling acquisition-ready leadership discipline.

What critics are saying

  • FDA safety concerns over AFX2 type III endoleaks still shadow AAA sales in 2026.
  • Milpitas closed in May 2026, eliminating 31 jobs and shrinking manufacturing capacity.
  • A serious AFX2 rupture case in 2026 reinforces litigation and recall exposure.

What makes Endologix unique

  • Endologix owns AFX2, ALTO, DETOUR, and Pounce, spanning AAA and PAD intervention.
  • DETOUR2 showed 58.2% primary patency and 97.9% major amputation freedom at 36 months.
  • Deerfield ownership enables long-horizon product consolidation, board upgrades, and tuck-in acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Flexible Work Hours
  • Hybrid Work Options
  • 401(k) Company Match
  • Company Equity
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Orange County Business Journal
May 19th, 2026
Endologix acquires Pounce System from Surmodics.

Endologix acquires Pounce System from Surmodics. Adds FDA-cleared device to vascular intervention portfolio Yuika Yoshida May 19, 2026 Irvine medical device maker Endologix today announced its acquisition of the Pounce Thrombectomy System from Minnesota-based Surmodics Inc. The Pounce System is an FDA-cleared device for the non-surgical removal of thrombi and emboli from peripheral arteries. "The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix," John Liddicoat, chief executive and president of Endologix, said in a statement. The acquisition expands Endologix' commercial offerings, which include its Detour, Alto and AFX2 platforms. Want more from the best local business newspaper in the country? Sign-up for its FREE Daily eNews update to get the latest Orange County news delivered right to your inbox! One-Year for Only $99 * Unlimited access to OCBJ.com * Daily OCBJ Updates delivered via email each weekday morning * Journal issues in both print and digital format * The annual Book of Lists: industry of Orange County's leading companies * Special Features: OC's Wealthiest, OC 500, Best Places to Work, Charity Event Guide, and many more!

Associated Press
May 7th, 2026
Endologix appoints Steve Deitsch to board following $1.5B OrganOx sale to Terumo

Endologix, a California-based medical device company focused on vascular disease treatments, has appointed Steve Deitsch to its board of directors. Deitsch brings over 25 years of global leadership experience in medtech and healthcare. Deitsch currently serves as chief executive officer of Caristo Diagnostics, an AI-focused cardiovascular disease company spun out from the University of Oxford. He previously served as chief financial officer of OrganOx, where he led the company's 2025 sale to Terumo Corporation for $1.5 billion, marking the largest spinout exit in Oxford's history. Endologix develops interventional therapies for vascular disease and is wholly owned by investment firm Deerfield Management. The company manufactures products including endovascular systems for abdominal aortic aneurysms and peripheral vascular disease.

Endologix LLC
May 7th, 2026
Endologix announces appointment of Steve Deitsch to Board of Directors.

Endologix announces appointment of Steve Deitsch to Board of Directors. Santa Rosa, Calif., May 7, 2026 - Endologix LLC, a privately held global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the appointment of Steve Deitsch to its Board of Directors. Mr. Deitsch brings more than 25 years of global leadership experience across medtech and the broader healthcare sector. He currently serves as Chief Executive Officer of Caristo Diagnostics, a global leader in AI technology for cardiovascular disease and a spinout from the University of Oxford. Previously, Mr. Deitsch was Chief Financial Officer of OrganOx, where he led the company's 2025 sale to Terumo Corporation for $1.5 billion, representing the largest spinout exit in the University of Oxford's history. "Having worked closely with Steve while on the OrganOx board, I've seen firsthand his strategic insight, financial acumen, and ability to execute complex transactions," said John Liddicoat, President and CEO of Endologix. "He will be a key voice for Endologix as we continue to build shareholder value and position the company for future strategic opportunities." Mr. Deitsch added, "I am delighted to join the outstanding Board of Directors at Endologix at such an exciting time. I have great respect for John, his leadership team, and Deerfield Management, and I look forward to working together to drive profitable growth." About Endologix Endologix LLC is a California-based, global medical device company dedicated to improving patients' lives by providing innovative therapies for the interventional treatment of vascular disease. The Endologix therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix commercial products, including the AFX(R) 2 Endovascular AAA System, ALTO(R) Abdominal Stent Graft System, and the DETOUR(TM) System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine and Santa Rosa, California. To learn more about Endologix, please visit https://endologix.com.

Yahoo Finance
Mar 26th, 2026
Endologix to close California facility, cut 31 jobs after PQ Bypass acquisition

Endologix plans to close its production facility in Milpitas, California, resulting in 31 redundancies scheduled for May and June. The vascular disease company acquired the site in 2021 through its takeover of PQ Bypass, gaining control of the Detour peripheral arterial disease device. The closure affects various manufacturing and quality roles, with most layoffs occurring on 6 May. Endologix operates additional offices and manufacturing facilities in Irvine and Santa Rosa, California, where it produces most commercial products. The move follows Endologix's 2020 Chapter 11 bankruptcy filing and subsequent emergence as a private company owned by Deerfield Partners. The company underwent leadership changes in 2024, appointing John Liddicoat as chief executive officer.

Business Wire
Mar 3rd, 2025
Endologix Appoints Andrew Davis as Chief Commercial Officer

Endologix appoints Andrew Davis as Chief Commercial Officer.